Reserpine

Tardive Dyskinesia (TD) Treatment Drugs Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022
Health, Pharmaceutical, FDA, Calcium channel, L-DOPA, Reserpine, Tardive dyskinesia, Amantadine, GCC, Prevalence, Benzodiazepine, TD, Neurological disorder, Vitamin E, Pharmaceutical industry, Bottled water

The "Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The report includes in-depth analysis of TD treatment drugs market for period from 2020 to 2029.
  • Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.
  • Based on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:
    For the purpose of this study, the global tardive dyskinesia (TD) treatment drugs market is categorized into:

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

Retrieved on: 
Monday, March 14, 2022
Hypertension, AmerisourceBergen, U.S. Securities and Exchange Commission, Therapy, Atropine, Degenerative disease, Private Securities Litigation Reform Act, Injection, Bradycardia, Bromide, Nervous, Oxytocin, Stroke, Growth, National, Intubation, New Drug Application, Carglumic acid, Safety, McKesson Corporation, Restless, Theophylline, FDA, Anesthesia, Tachyphylaxis, Temperature, Dizziness, Cardinal Health, MAOI, GLOBE, Nausea, Patient, Quinidine, Arrhythmia, Digitalis, Clonidine, XGen Studios, CEO, Ephedrine, Insomnia, Reserpine, Vomiting, Security (finance), Xanthine oxidase inhibitor, Ownership, Hypotension, Sulfite, Nasdaq, Incidence, Mephentermine, Guanethidine, Palpitations, Hospital, Tachycardia, Plasma protein binding, IQVIA, Goal, Pharmaceutical industry

DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.

Key Points: 
  • DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.
  • Rezipres (4.7 mg/mL) is a ready-to-use1 formulation of injectable ephedrine hydrochloride that is approved for the treatment of clinically important hypotension occurring in the setting of anesthesia.
  • We look forward to partnering with XGen DJB given their extensive track record of successfully commercializing injectable products in the hospital setting, said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • We are delighted to be teaming up with Eton as the commercial partner in introducing their ready-to-use Rezipres product, which is the first FDA-approved hydrochloride-based ephedrine injectable formulation, added Edmund Vanderbeck, President of XGen Pharmaceuticals DJB.